Published in Eur J Nucl Med Mol Imaging on August 15, 2008
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med (2009) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging (2014) 2.51
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 2.10
Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med (2011) 1.95
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55
Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. Med Phys (2010) 1.49
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Variability in PET quantitation within a multicenter consortium. Med Phys (2010) 1.46
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer (2010) 1.27
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. J Nucl Med (2015) 1.20
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.17
Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2013) 1.14
Optimized dose regimen for whole-body FDG-PET imaging. EJNMMI Res (2013) 1.12
Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging (2011) 1.11
Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging (2009) 1.11
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
SUVref: reducing reconstruction-dependent variation in PET SUV. EJNMMI Res (2011) 1.02
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging (2011) 1.01
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging (2017) 1.00
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging (2013) 0.99
Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. Eur J Nucl Med Mol Imaging (2011) 0.99
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology (2016) 0.97
In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res (2014) 0.94
The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol (2010) 0.93
Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc (2012) 0.93
Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off. Eur Radiol (2010) 0.92
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials. Magn Reson Imaging (2012) 0.91
The distribution of FDG at PET examinations constitutes a relative mechanism: significant effects at activity quantification in patients with a high muscular uptake. Eur J Nucl Med Mol Imaging (2012) 0.90
A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres : The QUEST Phantom Study. Eur J Nucl Med Mol Imaging (2015) 0.90
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging (2013) 0.90
Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on (18)F-FDG PET-CT for radiotherapy treatment planning. Rep Pract Oncol Radiother (2012) 0.89
FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB (Oxford) (2011) 0.89
PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2013) 0.89
Variability of Image Features Computed from Conventional and Respiratory-Gated PET/CT Images of Lung Cancer. Transl Oncol (2015) 0.88
Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2013) 0.87
Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging (2012) 0.87
The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. Cancer Imaging (2014) 0.86
Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. BMC Cancer (2014) 0.85
The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging (2013) 0.85
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging (2009) 0.85
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol (2013) 0.83
Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging (2015) 0.83
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging (2014) 0.82
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica (2011) 0.82
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS One (2015) 0.81
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys (2008) 0.81
Scanning linear estimation: improvements over region of interest (ROI) methods. Phys Med Biol (2013) 0.81
The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. BMC Cancer (2013) 0.81
Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results. Patholog Res Int (2011) 0.81
Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands. Eur Arch Otorhinolaryngol (2014) 0.80
Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int (2012) 0.80
18F-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin. PLoS One (2013) 0.79
Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT. PLoS One (2013) 0.79
Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther (2016) 0.78
Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats. Adv Hematol (2010) 0.78
Comparison of [18 F]FDG PET/CT and MRI in the diagnosis of active osteomyelitis. Skeletal Radiol (2014) 0.78
Performance Observations of Scanner Qualification of NCI-Designated Cancer Centers: Results From the Centers of Quantitative Imaging Excellence (CQIE) Program. Acad Radiol (2016) 0.77
18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging (2011) 0.77
Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer. Ann Nucl Med (2015) 0.77
A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. Transl Oncol (2014) 0.77
Semi-quantitative investigation of primary tumor and bone metastasis in lung cancer patients using the PET-CT approach. Int J Clin Exp Med (2014) 0.77
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. Croat Med J (2015) 0.76
Radiation Dose from Whole-Body F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Nationwide Survey in Korea. J Korean Med Sci (2016) 0.75
(18)F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases. Eur J Nucl Med Mol Imaging (2017) 0.75
A Review of NIST Primary Activity Standards for (18)F: 1982 to 2013. J Res Natl Inst Stand Technol (2014) 0.75
Comparison of the Performances of (18)F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nucl Med Mol Imaging (2016) 0.75
Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy. Radiol Med (2014) 0.75
Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. PLoS One (2016) 0.75
Predicting tumour response to chemoradiotherapy in oesophageal cancer by early interim 18F-FDG PET: where do we stand and where should we go? Eur J Nucl Med Mol Imaging (2013) 0.75
Incorporating prognostic imaging biomarkers into clinical practice. Cancer Imaging (2013) 0.75
Fluorine-18-fluorodeoxyglucose positron emission tomography in assessing retroperitoneal fibrosis: a literature review. Int J Mol Imaging (2012) 0.75
Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma. Braz J Med Biol Res (2015) 0.75
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. Eur J Nucl Med Mol Imaging (2016) 0.75
Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients. PLoS One (2014) 0.75
A method to obtain correct standard uptake values in Pinnacle treatment planning system for target volume delineation. J Med Phys (2017) 0.75
Qualification of NCI-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials. J Nucl Med (2017) 0.75
The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials. Biomedicines (2016) 0.75
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med (2004) 6.10
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med (2005) 3.26
Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med (2004) 2.97
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med (2005) 2.52
Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys (2004) 2.17
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol (2006) 2.01
Positron emission tomography as an imaging biomarker. J Clin Oncol (2006) 1.84
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev (2004) 1.60
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer (2007) 1.50
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med (2006) 1.40
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J (2001) 1.34
FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study. Nucl Med Commun (2007) 1.29
A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun (2007) 1.27
Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med (2005) 1.16
PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging (2005) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol (2002) 1.08
CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging (2002) 1.01
Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med (2005) 1.01
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging (2004) 0.99
Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med (2003) 0.96
Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med (2003) 0.95
Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods. J Nucl Med Technol (2003) 0.95
CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys (2001) 0.92
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol (2002) 0.88
Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol (2003) 0.87
Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med (2005) 0.84
Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer. Ann Nucl Med (2007) 0.84
Cancer of unknown primary. Recent Results Cancer Res (2008) 0.82
Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imaging (2005) 0.82
Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging (2007) 0.78
Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm. Eur J Nucl Med Mol Imaging (2008) 0.78
Clinical experience with a commercially available negative oral contrast medium in PET/CT. Rofo (2005) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med (2004) 6.10
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (2002) 3.67
Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol (2009) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62
Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys (2005) 2.62
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol (2002) 2.56
Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. Lancet Oncol (2011) 2.36
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol (2006) 2.01
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00
Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest (2005) 1.97
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med (2009) 1.88
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol (2003) 1.86
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. Radiology (2005) 1.84
Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med (2012) 1.78
18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 1.75
Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71
18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging (2011) 1.63
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica (2006) 1.61
99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61
18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med (2009) 1.59
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. Radiology (2005) 1.56
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55
F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55
PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55
Quantitative relationship between coronary artery calcium score and hyperemic myocardial blood flow as assessed by hybrid 15O-water PET/CT imaging in patients evaluated for coronary artery disease. J Nucl Cardiol (2011) 1.54
Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54
Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med (2008) 1.50
Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer (2007) 1.50
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48
68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging (2010) 1.48
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med (2002) 1.48
A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47
Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med (2010) 1.47
Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med (2010) 1.46
Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer (2005) 1.46
Clinicians are right not to like Cohen's κ. BMJ (2013) 1.44
Bone SPECT reduces the number of unnecessary mandibular resections in patients with squamous cell carcinoma. Oral Oncol (2005) 1.44
FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging (2006) 1.44
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun (2007) 1.41
99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med (2002) 1.41
Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging (2010) 1.40
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood (2006) 1.39
Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer (2006) 1.38
Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med (2006) 1.37
Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging (2002) 1.36